GSTM1 and anemia: A randomized, single-person, placebo-controlled, phase 2a study (NCT00761657; n = 116) in patients with anemia and terminal renal failure, not treated by hemodialysis, showed that roxadustat, used three times a week, increased Hb levels by dose (0.8–2.2 mg/dg/dL) during the 6-week study period (4 weeks of treatment), with a significant difference between the roxadustat groups of 1.5 and 2.0 mg/kg, compared to a placebo group (the mean change +1.2 and +1.8 vs. −0.1 g/dL; both p < 0.01; [10]) (Table 1) [13].